Key Highlights
- Navan shares skyrocketed 19% following an earnings beat and upgraded full-year outlook
- Oracle declined 10% as concerns over its $40B fundraising plan overshadowed solid quarterly performance
- Humacyte shares slid 16% following a dilutive share offering priced at $1.05
- PureCycle declined 14% on news of $395M in capital raising activities
- S&P 500 futures advanced 0.60% as investors shook off Wednesday’s technology-driven market selloff
U.S. equity futures posted solid gains in Thursday’s pre-market session as investors looked to recover ground following Wednesday’s steep decline, which was primarily fueled by anxiety surrounding artificial intelligence stocks.
Market confidence received a boost after crude oil prices retreated. Washington confirmed the conclusion of retaliatory military operations against Iran, temporarily alleviating worries about potential escalation in the region.
S&P 500 futures climbed 0.60%, with Dow Jones futures adding 0.69%. Meanwhile, the benchmark 10-year Treasury yield eased to 4.526%.
During Wednesday’s regular trading, the S&P 500 tumbled 1.62% while the Dow Jones Industrial Average shed 1.87%. Overnight, Asian equity markets delivered mixed results, with Japan’s Nikkei posting modest gains while China’s Shanghai Composite edged into negative territory.
Bitcoin advanced 1.93% to reach $63,095 during early morning hours. Gold futures declined 0.64%, and Brent crude oil retreated 1.17%.
Navan Dominates the Winner’s Circle
Navan emerged as Thursday morning’s most impressive performer, with its stock price soaring 19% during pre-market activity.
The corporate travel and expense platform delivered first-quarter financial results that substantially exceeded Wall Street’s projections. Non-GAAP earnings per share reached $0.08, surpassing analyst estimates by $0.07.
Revenue totaled $220.3 million, beating consensus forecasts by $15 million.
The company also elevated its full-year projections. Navan now anticipates fiscal 2027 revenue ranging from $907 million to $913 million, indicating approximately 30% year-over-year expansion.
Profitability expectations also received an upgrade, with non-GAAP operating income now projected between $76 million and $80 million.
AXT climbed 7.3% in pre-market action. Spyre Therapeutics, Coupang, and Tower Semiconductor each registered gains exceeding 6%.
Oracle Tumbles Despite Strong Financial Performance
Oracle ranked among Thursday morning’s most significant decliners, dropping approximately 10% even after delivering impressive quarterly earnings.
Fourth-quarter revenue increased 21% year over year to reach $19.2 billion. Adjusted earnings per share of $2.11 exceeded analyst projections.
Cloud infrastructure revenue surged 93%, while overall cloud revenue expanded 47%. The enterprise software giant also disclosed a $638 billion remaining performance obligation backlog, propelled by substantial AI-related contracts.
Oracle projected fiscal 2027 revenue at $90 billion, surpassing Street expectations.
Neverthstanding these positive metrics, shareholders sent the stock lower. Primary concerns centered on weakening legacy software revenue and the company’s strategy to raise $40 billion through a combination of debt and equity financing to support AI data center expansion initiatives.
Humacyte plunged 16% following the announcement of a public offering comprising 47.6 million shares priced at $1.05 each, generating approximately $50 million in proceeds.
PureCycle tumbled 14% after revealing $395 million in combined capital raising efforts, encompassing $250 million in convertible debt securities and an equity offering priced at $8.21 per share.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
